Polomar Health Services, Inc.
Datakwaliteit: 100%
PMHS
OTC
Manufacturing
Chemicals
€ 0,16
€ 0,00
(0,00%)
Marktkapitalisatie: 4,49 M
Prijs
€ 0,16
Marktkapitalisatie
4,49 M
Dagbereik
€ 0,08 — € 0,08
52-Weeksbereik
€ 0,07 — € 0,80
Volume
1
Openen € 0,08
50D / 200D Gem.
€ 0,28
41,86% below
50D / 200D Gem.
€ 0,30
46,97% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -991.904,0
Capital intensive — 245,36% of revenue goes to capex
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)70,38%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-30,08%
Boven sectorgemiddelde (-53,47%)
ROIC-22,45%
Net Margin-6562,42%
Op. Margin-6199,82%
Veiligheid
Debt / Equity
N/A
Current Ratio0,13
Interest Coverage-17,10
Waardering
PE (TTM)
-1,85
Onder sectorgemiddelde (-1,47)
P/B Ratio0,58
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -1,9 | -1,5 |
| P/B | 0,6 | 1,6 |
| ROE % | -30,1 | -53,5 |
| Net Margin % | -6562,4 | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 70,38% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 37.044,0 | Net Income (TTM) | -2,43 M |
| ROE | -30,08% | ROA | -26,00% |
| Gross Margin | 55,09% | Operating Margin | -6199,82% |
| Net Margin | -6562,42% | Free Cash Flow (TTM) | -991.904,0 |
| ROIC | -22,45% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,13 |
| Interest Coverage | -17,10 | Asset Turnover | 0,00 |
| Working Capital | -1,31 M | Tangible Book Value | 7,77 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1,85 | Forward P/E | N/A |
| P/B Ratio | 0,58 | P/S Ratio | 121,17 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -22,10% | ||
| Market Cap | 4,49 M | Enterprise Value | 4,45 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,09 | Revenue / Share | 0,00 |
| FCF / Share | -0,04 | OCF / Share | -0,03 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | 245,36% | FCF Conversion | 40,80% |
| SBC-Adj. FCF | -1,12 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2024 | FY2023 |
|---|---|---|
| Revenue | 58.824,0 | 34.526,0 |
| Net Income | -1,34 M | -416.500,0 |
| EPS (Diluted) | -0,05 | -0,02 |
| Gross Profit | 30.903,0 | 34.526,0 |
| Operating Income | -1,30 M | -269.830,0 |
| EBITDA | — | — |
| R&D Expenses | — | — |
| SG&A Expenses | — | — |
| D&A | 263.280,0 | — |
| Interest Expense | 41.837,0 | — |
| Income Tax | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2024 | FY2023 |
|---|---|---|
| Total Assets | 9,95 M | 244,0 |
| Total Liabilities | 1,35 M | 13.783,0 |
| Shareholders' Equity | 8,60 M | -13.539,0 |
| Total Debt | — | — |
| Cash & Equivalents | 6.191,0 | 224,0 |
| Current Assets | 76.813,0 | 244,0 |
| Current Liabilities | 1,34 M | 13.783,0 |
{"event":"ticker_viewed","properties":{"ticker":"PMHS","listing_kind":"stock","pathname":"/stocks/pmhs","exchange":"OTC","country":"US"}}